{
    "title": "AstraZeneca has two cancer drugs approved for use in the EU just days after lung cancer trial setback",
    "url": "https://www.dailymail.co.uk/money/markets/article-11562263/AstraZeneca-two-cancer-drugs-approved-use-EU.html",
    "date": "2022-12-21",
    "keywords": [
        "cancer",
        "treatment",
        "astrazeneca",
        "imfinzi",
        "combination",
        "chemotherapy",
        "approval",
        "tract",
        "lynparza",
        "prostate",
        "abiraterone",
        "trial",
        "risk",
        "share",
        "fund",
        "light",
        "eu",
        "lung",
        "drug",
        "death",
        "cent",
        "versus",
        "business",
        "need",
        "disease",
        "progression",
        "castrationresistant",
        "investment",
        "account",
        "fee",
        "use",
        "unionthe",
        "ftse",
        "pharma",
        "giant",
        "adult",
        "meanwhile",
        "medication",
        "astrazenecas",
        "union",
        "medicationsit",
        "survivability",
        "latestage",
        "immunotherapy",
        "moment",
        "europeastra",
        "boost",
        "space",
        "watchdog",
        "licence",
        "article",
        "vice",
        "president",
        "oncology",
        "unit",
        "option",
        "commitment",
        "europe",
        "line",
        "therapy",
        "fredrickson",
        "advance",
        "euthe",
        "year",
        "company",
        "japan",
        "back",
        "today",
        "diy",
        "capital",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "money",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}